Although a link between sickle cell disease and resistance to severe malaria is well established, the biochemical relationship between the two is unknown. Ferreira et al. (2011) show that carriers of the sickle cell mutation increase expression of the heme oxygenase-1 enzyme, which produces antioxidant molecules that may prevent severe disease symptoms.
Sickle cell disease is a recessive genetic disorder caused by mutation of the hemoglobin gene. In affected individuals, red blood cells display an abnormal ''sickled'' morphology and show altered biophysical properties. The epidemiological relationship between sickle cell disease and severe malaria, caused by Plasmodium parasites infecting red blood cells, is well established (Allison, 1954) . Homozygous individuals, carrying two copies of the mutated ''sickle'' haemoglobin allele, the HbS allele, develop sickle cell disease. Heterozygotic carriers (having the ''sickle cell trait''), on the other hand, are spared disease symptoms but show significant resistance to severe malaria syndromes such as cerebral malaria, a neurological complication of the infection that can induce long-term cognitive impairment and death. Retention of the HbS allele within the human gene pool, specifically in those with sub-Saharan African ancestry, can thus be explained by the survival benefit it has afforded to heterozygotic carriers living in malaria-endemic areas. However, the biochemical basis for resistance to severe malaria in heterozygous individuals has remained elusive.
In this issue of Cell, Ferreira et al. (2011) provide intriguing in vivo evidence that HbS heterozygous individuals may be tolerant to Plasmodium infection due to upregulation of heme oxygenase-1 (HO-1), an enzyme that normally recycles the contents of spent red blood cells in the spleen. In individuals carrying the HbS allele, heme levels are higher. Ferreira et al. suggest that HO-1 converts the free heme into antioxidant molecules that may protect against oxidative damage caused by severe malaria and may also prevent a pathological immune response.
This group has previously shown that HO-1 and a product of its activity, carbon monoxide (CO), can protect Plasmodium-infected mice from developing fatal neurological symptoms, in an experimental model that displays similarities to human cerebral malaria (Pamplona et al., 2007) . Whereas carbon monoxide is toxic at high concentrations, at low levels it plays important and varied physiological roles, for example as a neurotransmitter, vasorelaxant, and perhaps crucially, as an anti-inflammatory agent. Inflammatory and cellular immune responses play pivotal roles in mediating cerebral malaria in mice (although the roles of these responses in the pathogenesis of human cerebral malaria are still unclear). HO-1 and carbon monoxide have been shown to substantially reduce neurological inflammation, in particular the accumulation of CD8 + T cells in the brain (Pamplona et al., 2007) . In this study, the authors employ a transgenic mouse carrying a human HbS allele to model carriers of the sickle cell trait. They find that these mice are resistant to murine cerebral malaria, whereas control mice, expressing wild-type human hemoglobin, are susceptible to the disease. Based on their previous work (Pamplona et al., 2007) , the authors hypothesized that HO-1 may play a role in HbS-mediated protection. By knocking out single alleles of either HO-1 or the transcriptional regulator nrf2 in mice carrying the HbS allele, they also show that protection from murine cerebral malaria depends on HO-1, which is in turn controlled by Nrf2. Finally, carbon monoxide inhalation protects HO-1 knockout mice carrying the HbS allele from Plasmodium-induced neurological disease. These results demonstrate a critical role for HO-1-induced carbon monoxide in neuroprotection in this disease model. Thus, the authors clearly show in an in vivo model of sickle cell trait carriers that protection from severe malaria depends upon HO-1, which is elevated in the hematopoietic cells of such individuals.
In murine cerebral malaria, disease severity is closely linked to the number of parasites in the whole body, known as parasite biomass (Amante et al., 2010) . The study by Ferreira et al. now suggests that HbS, HO-1, and carbon monoxide protect against cerebral malaria without affecting parasite biomass, leading the authors to speculate that HbS renders the host more tolerant of Plasmodium parasites. Previous models suggested that HbS inhibits the adherence of parasitized red blood cells to host endothelial tissues (Cholera et al., 2008) , prevents parasite invasion or growth within red blood cells (Hood et al., 1996) , or triggers improved immunity (Cabrera et al., 2005) . The model proposed by Ferreira et al. is conceptually different from the previous ideas because it describes HbS-mediated tolerance, not a reduction in parasite numbers or virulence.
But how could sickle hemoglobin produce a more tolerant host? Previous studies suggest that, compared to noncarriers, humans who are either homozygous or heterozygous for the HbS allele have higher levels of free heme in the blood (i.e., heme that is not safely contained within the hemoglobin protein) (Muller-Eberhard et al., 1968) . Although free heme is potentially toxic, due to its oxidative properties, it is neutralized by HO-1. HO-1 catalyzes the conversion of free heme to carbon monoxide and biliverdin and releases labile iron (Fe) to bind to another protein called ferritin H chain (FtH) (Figure 1 ). Biliverdin can be converted to bilirubin, which, along with FtH and carbon monoxide, protects against oxidative damage. Thus, individuals carrying the HbS allele may be better equipped to deal with oxidative stress, but whether this occurs during cerebral malaria remains to be established, particularly given evidence of reduced oxidative metabolism in the brain during this disease. Nevertheless, HO-1 has been detected in leukocytes in the brains of malaria patients who died of cerebral malaria (Medana et al., 2001) . Future work may establish whether HO-1 plays a tissue-protective role in the brain during malaria, and whether HO-1 levels are higher in those who survive cerebral malaria compared to those who die.
A defining characteristic of the murine cerebral malaria model is that relatively low numbers of CD8 + T cells, which are beneficial in other diseases because they kill infected cells and tumors, appear to cause catastrophic neurological pathology. Ferreira and colleagues show that the HbS allele, HO-1, and carbon monoxide all substantially inhibit the accumulation of CD8 + T cells in the brain.
Therefore, it is likely that HbS protects mice against cerebral malaria, at least partially, by inhibiting CD8 + T cell
responses. An important future task will be to determine the relative importance of cytoprotection (i.e., protection against oxidative damage) versus immune-cell regulation in the protection afforded by sickle hemoglobin, HO-1, and carbon monoxide. Moreover, it will be important, although technically challenging, to establish whether or not small numbers of highly pathogenic CD8 + T cells are recruited to the brains of patients suffering from cerebral malaria. Finally, there seems to be a fine balance that determines whether free heme is protective or pathogenic during malaria. Whereas modest increases in free heme may protect individuals with the sickle cell trait from cerebral malaria by enhancing HO-1 expression, a more substantial elevation in free heme levels appears to play a pathogenic role by scavenging nitric oxide. Low levels of nitric oxide have been linked to endothelial dysfunction in human (Yeo et al., 2007) and mouse severe malaria.
In summary, Ferreira and colleagues provide a novel explanation for the 50-year-old conundrum of why HbS carriers are resistant to severe malaria. Further elucidation of the biochemical and immunological mechanisms at play in HbS carriers could pave the way for new therapeutic strategies to treat the many thousands of malaria patients who die each year from severe malaria complications. The figure shows a molecular pathway that may explain why carriers of the sickle cell trait, who are heterozygous for the mutation that causes the disease (HbS), may have more resistance to severe malaria symptoms. Mice harboring the human HbS allele have elevated levels of free heme in the blood. Free heme is toxic and can cause oxidative damage, but its effects are suppressed by the upregulation of heme oxygenase-1 (HO-1), which converts heme into the antioxidant molecules carbon monoxide (CO) and biliverdin and releases iron to bind to ferritin H chain (FtH). HO-1 expression is regulated by Nrf2. In individuals with the sickle cell trait, the elevated levels of carbon monoxide prior to infection may inhibit pathogenic CD8 + T cell immune responses and also prevent oxidative tissue damage during severe malaria.
